Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00131014 · ClinicalTrials.gov registry record
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
A clinical trial of Non-Hodgkin's Lymphoma and Hodgkin's Disease, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 1
- Study location
NCT00131014 is a study of Non-Hodgkin's Lymphoma and Hodgkin's Disease that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 1,500 participants, above the 198-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (658% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00131014, a study of Non-Hodgkin's Lymphoma and Hodgkin's Disease, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different from sporadic lymphomas and to attempt to identify a gene that confers an increased risk of lymphoma.
Conditions Studied
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2004-08-09 |
| Est. Completion | 2033-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00131014
The ClinicalTrials.gov registry entry for NCT00131014 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 198-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (658% higher). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 0 interventions.
NCT00131014 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00131014 about?
NCT00131014 is a clinical study titled "Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies". The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different from sporadic lymphomas and to attempt to identify a gene that confers...
What is the current status of trial NCT00131014?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2004-08-09. Estimated completion is 2033-01.
What conditions does trial NCT00131014 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma, Hodgkin's Disease, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic.
Who is sponsoring clinical trial NCT00131014?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00131014 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
Cord Blood Transplant in Adults With Blood Cancers
RECRUITING · Phase 2
-
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
RECRUITING
-
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
RECRUITING · Phase 1
-
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.